Key result
Hepatic Phd disruption in mice increases EPO ~1246-fold and maintains hematocrit during chronic renal failure.
Hepatic PHD2 and PHD3 deficiency induces liver EPO expression sufficient to maintain normal hematocrit in a mouse model of chronic renal failure without causing severe vascular malformation or steatosis.
Does not support changing CKD anemia therapy; hypothesis-generating for hepatic PHD2/3 targeting to sustain hematocrit in renal failure models.
Prolyl hydroxylase domain (PHD) proteins catalyze oxygen-dependent prolyl hydroxylation of hypoxia-inducible factor 1α and 2α, tagging them for pVHL-dependent polyubiquitination and proteasomal degradation. In this study, albumin Cre (Alb(Cre))-mediated, hepatocyte-specific triple disruption of Phd1, Phd2, and Phd3 (Phd(1/2/3)hKO) promoted liver erythropoietin (EPO) expression 1246-fold, whereas renal EPO was down-regulated to 6.7% of normal levels. In Phd(1/2/3)hKO mice, hematocrit levels reached 82.4%, accompanied by severe vascular malformation and steatosis in the liver. In mice double-deficient for hepatic PHD2 and PHD3 (Phd(2/3)hKO), liver EPO increase and renal EPO loss both occurred but were much less dramatic than in Phd(1/2/3)hKO mice. Hematocrit levels, vascular organization, and liver lipid contents all appeared normal in Phd(2/3)hKO mice. In a chronic renal failure model, Phd(2/3)hKO mice maintained normal hematocrit levels throughout the 8-week time course, whereas floxed controls developed severe anemia. Maintenance of normal hematocrit levels in Phd(2/3)hKO mice was accomplished by sensitized induction of liver EPO expression. Consistent with such a mechanism, liver HIF-2α accumulated to higher levels in Phd(2/3)hKO mice in response to conditions causing modest systemic hypoxia. Besides promoting erythropoiesis, EPO is also known to modulate retinal vascular integrity and neovascularization. In Phd(1/2/3)hKO mice, however, neonatal retinas remained sensitive to oxygen-induced retinopathy, suggesting that local EPO may be more important than hepatic and/or renal EPO in mediating protective effects in the retina.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2014) studied Prolyl Hydroxylase Domain Protein deficiency in the liver / Chronic renal failure. Hepatocyte-specific disruption of Phd1, Phd2, and Phd3 (Phd(1/2/3)hKO) or Phd2 and Phd3 (Phd(2/3)hKO) vs. Floxed controls was evaluated on Liver erythropoietin (EPO) expression and hematocrit levels. Hepatocyte-specific triple disruption of Phd1, 2, and 3 in mice increased liver EPO expression 1246-fold and hematocrit to 82.4%, while Phd2/3 double-deficient mice maintained normal hematocrit in chronic renal failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: